Axogen completes acquisition of BioCircuit Technologies

Bitget2026/10/01 21:20

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Axogen completed the acquisition of privately held BioCircuit Technologies, adding the NerveTape device for sutureless peripheral nerve repair.
BioCircuit is expected to contribute about $6 million of revenue in Q4 2026.
Projected 2027 revenue contribution is about $34 million, not included in Axogen’s latest 2026 outlook of at least 24% growth.
Axogen reiterated full-year 2026 gross margin guidance of at least 73%.
The company maintained its expectation to be free cash flow positive for full-year 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610011719PRIMZONEFULLFEED9838295) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Axogen completes acquisition of BioCircuit Technologies

You may also like

Crypto prices